1. Switch to tacrolimus for cyclosporine-induced gynecomastia in liver transplant recipients
- Author
-
Franco Mosca, Laura Coletti, P De Simone, Lucio Urbani, Paola Carrai, Franco Filipponi, Gabriele Catalano, Stefania Petruccelli, C Garcia, Luca Morelli, R Liermann, and G Iaria
- Subjects
Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Cholangitis, Sclerosing ,Urology ,Tacrolimus ,Postoperative Complications ,Internal medicine ,medicine ,Humans ,Testosterone ,skin and connective tissue diseases ,Antibacterial agent ,Transplantation ,business.industry ,Liver Neoplasms ,Luteinizing Hormone ,Middle Aged ,Ciclosporin ,medicine.disease ,Liver Transplantation ,Prolactin ,Calcineurin ,Endocrinology ,Gynecomastia ,Concomitant ,Cyclosporine ,Surgery ,Luteinizing hormone ,business ,Immunosuppressive Agents ,medicine.drug - Abstract
We report herein on two male liver transplant (LT) recipients who presented with cyclosporine (CsA)-related gynecomastia 6 and 10 months after transplantation. The clinical workup showed increased luteinizing hormone (LH), associated with a slight reduction in testosterone blood levels in one patient and increased prolactin levels in the other. After excluding concomitant primary endocrine and/or malignant disease, conversion to tacrolimus (TAC) was performed resulting in clinical improvement of gynecomastia and return of hormone blood levels to normal range within 3 months. Our report confirms a putative role of CsA in post-LT gynecomastia, reversible however upon conversion to TAC.
- Published
- 2005